NICE green lights Tremfya to treat active psoriatic arthritis
Tremfya has already been recommended for NHS use to treat eligible patient with moderate-to-severe plaque psoriasis
Read More
Tag: Tremfya
Janssen’s Tremfya approved for active psoriatic arthritis
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Read More
Janssen’s psoriasis med Tremfya scores long-term safety and efficacy data
Treatment demonstrated positive outcomes for nearly five years
Read More
Janssen’s Tremfya wins psoriatic arthritis approval
The drug is the first IL-23 inhibitor approved for the condition
Read More
Taltz trumps Tremfya in plaque psoriasis study
The drug met the primary and all major secondary endpoints up to week 12 in the Phase IV IXORA-R study.
Read More
Tremfya tops Cosentyx in late-stage study
The study is the first to compare Tremfya and the IL-17 inhibitor, Cosentyx.
Read More
Tremfya gets FDA approval in moderate-to-severe plaque psoriasis
Janssen has announced FDA approval of its novel drug Tremfya for adults with moderate-to-severe plaque psoriasis.
Read More
Plaque psoriasis study claims Tremfya superior to Cosentyx
Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis’ Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study.
Read More
Janssen launches PhII/III programme testing Tremfya in Crohn’s
Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease.
Read More
Final NICE nod for Janssen’s Tremfya
The National Institute for Health and Care Excellence (NICE) has now issued guidance recommending Janssen’s Tremfya as an option for treating plaque psoriasis in adults on the NHS.
Read More
SMC approves funding for six new therapies on the NHS
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read More
Janssen’s Tremfya backed for NHS use
Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
